Global Malignant Glioma API Manufacturers, Marketed and Phase III Drugs Landscape Report 2017-2018 - Research and Markets
February 17 2017 - 11:39AM
Business Wire
Research and Markets has announced the addition of the
"Malignant Glioma - Global API Manufacturers, Marketed and Phase
III Drugs Landscape, 2017" drug pipelines to their offering.
Malignant Glioma - Global API Manufacturers, Marketed and Phase
III Drugs Landscape, 2017, provides comprehensive insights about
the marketed drugs, drug sales, Phase III pipeline drugs and their
API Manufacturers across the globe.
A key objective of the Malignant Glioma Report is to understand
the market and pipeline status of the drugs around the Malignant
Glioma to explore the generic development opportunities, licensing
opportunities and to gain competitive advantage on designing
pipeline strategies. The Report provides the historical and
forecasted sales of the drugs till 2018.
The Malignant Glioma Report gives insights into patents
providing the patent protection data and marketing exclusivity of
all the drugs across the Malignant Glioma.
While the leading brands, companies and chemicals are considered
thoroughly, the report also provides details on the Global API
Manufacturers across the globe covering Drug Master Filings of US,
Europe and API Manufacturers in Asia specifically China and
India.
Key Topics Covered:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Malignant Glioma
7. Phase III Drugs for Malignant Glioma
8. Discontinued Drugs for Malignant Glioma
9. Appendix
For more information about this drug pipelines report visit
http://www.researchandmarkets.com/research/c8kg5k/malignant_glioma
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170217005542/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Related Topics: Brain Cancer Drugs